Granules India's shares fell nearly 8% after the US FDA issued a warning letter regarding its Gagillapur facility, citing ...

Granules added that manufacturing and distribution of its existing products at the facility will continue unaffected.

"On February 26, 2025, the US FDA issued a Warning Letter to Granules' Gagillapur facility based on its inspection conducted ...

Drug firm Granules India Ltd on Thursday (February 27) announced that the US FDA has issued a Warning Letter for its ...

In a bid to break into the CDMO business at one of its most lucrative angles, India's Granules is snapping up Swiss contract ...

TP Solar Limited, Tata Power’s solar manufacturing arm, has bagged a Rs 632 crore worth contract from SECI. The Tata group ...

The development may temporarily delay the approval of pending product submissions from the site, but existing manufacturing ...

The Warning Letter is dated February 26, 2025 and the facility continues to hold an "Official Action Indicated" (OAI) status.

Generic drugmaker Granules India is foraying into the peptide segment and contract development and manufacturing organisation ...

Granules India's Gagillapur facility receives FDA warning letter, impacting product submissions review until resolved, company remains confident in resolution.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

New research suggests that the formation of stress granules, clumps of proteins and RNA under stress, is a potential root ...